EIKN Eikon Therapeutics, Inc.
$8.94▼ -2.93%
Healthcare
Other
After hours
$8.94▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.01M
Avg Volume (10D) 418.1K
Key Metrics & Fundamentals
Market Cap
$484.24M
P/E Ratio
–
Div Yield
–%
52W Range
7.90 - 17.40
% vs 50 MA
-14.19%
% vs 200 MA
–%
RSI-14
37.5
MACD Histogram
-0.2700
Beta (1Y vs SPY)
2.41
Free Cash Flow
-$65.21M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$88.34M
COGS
–
Operating Exp
$93.39M
Operating Income
-$93.39M
EBIT
-$93.39M
Pretax Income
-$88.41M
Net Income
-$88.41M
EPS (Diluted)
-1.63
Price & Volume History
Loading chart…
Recent News
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
GlobeNewswire · Sep 3, 2026 11:30 AM
Eikon Therapeutics to Participate in Investor Conferences in September 2026
GlobeNewswire · Aug 26, 2026 11:30 AM
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
MarketBeat · Aug 22, 2026 11:01 AM
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
GlobeNewswire · Aug 18, 2026 8:15 PM
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire · Aug 13, 2026 8:02 PM
Eikon Therapeutics Selects Dose in Phase 2/3 Trial of Investigational Melanoma Treatment
MT Newswires · Aug 11, 2026 12:41 PM
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
GlobeNewswire · Aug 11, 2026 11:30 AM
Eikon Therapeutics Doses First Patient in Phase 2/3 Trial for EIK1001 in Non-Small Cell Lung Cancer
MT Newswires · Jul 27, 2026 12:16 PM
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
GlobeNewswire · Jul 27, 2026 11:30 AM
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
GlobeNewswire · Jul 20, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See EIKN's money flow as a full page
Social Sentiment
No Reddit posts found for EIKN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.